Wave Life Sciences Ltd. (WVE)Healthcare | Biotechnology | Singapore, Singapore | NasdaqGM
5.99 USD
-0.14
(-2.365%) ⇩
(July 15, 2026, 10:20 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:39 a.m. EDT
Wave Life Sciences presents a classic value trap scenario where the market has priced out the business entirely due to deteriorating fundamentals. The company is burning cash aggressively, with negative operating cash flow and gross margins, while the stock has lost nearly two-thirds of its value over the last nine years. Despite a recent year-over-year price recovery, the underlying economics remain broken, making this a poor long-term hold. On the short end, the heavy put open interest suggests traders are hedging against further declines rather than betting on a catalyst-driven surge, keeping the immediate outlook muted. With no dividend to provide income and a balance sheet showing significant operational bleed, investors should avoid this security until the path to profitability becomes clear. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.180222 |
| AutoARIMA | 0.180224 |
| AutoTheta | 0.185309 |
| MSTL | 0.199271 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.178 |
| Excess Kurtosis | -0.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.071 |
| Revenue per Share | 0.403 |
| Market Cap | 1,151,527,296 |
| Forward P/E | -5.52 |
| Beta | -1.30 |
| Profit Margins | -255.70% |
| Website | https://wavelifesciences.com |
As of July 11, 2026, 2:39 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by significant put volume and open interest at strikes well below the current price (e.g., $5.00 and $6.00). While there is some call activity at distant strikes ($20-$33), the overwhelming majority of open interest sits in the out-of-the-money put territory, suggesting a bearish bias or a 'buy the dip' strategy rather than a rally expectation.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.21611255 |
| Address1 | Marina One East Tower |
| Address2 | 7 Straits View No.12-00 |
| All Time High | 56.0 |
| All Time Low | 1.16 |
| Ask | 7.6 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 2,887,710 |
| Average Daily Volume3 Month | 3,752,081 |
| Average Volume | 3,752,081 |
| Average Volume10Days | 2,887,710 |
| Beta | -1.295 |
| Bid | 4.38 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 2.762 |
| City | Singapore |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | Singapore |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.985 |
| Current Ratio | 11.264 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.12 |
| Day Low | 5.94 |
| Debt To Equity | 3.071 |
| Display Name | Wave Life Sciences |
| Earnings Call Timestamp End | 1,777,379,400 |
| Earnings Call Timestamp Start | 1,777,379,400 |
| Earnings Timestamp | 1,777,379,400 |
| Earnings Timestamp End | 1,785,328,200 |
| Earnings Timestamp Start | 1,785,328,200 |
| Ebitda | -193,471,008 |
| Ebitda Margins | -2.69466 |
| Enterprise To Ebitda | -3.362 |
| Enterprise To Revenue | 9.059 |
| Enterprise Value | 650,413,248 |
| Eps Current Year | -0.83755 |
| Eps Forward | -1.08388 |
| Eps Trailing Twelve Months | -1.05 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.2922 |
| Fifty Day Average Change | -0.30719995 |
| Fifty Day Average Change Percent | -0.048822343 |
| Fifty Two Week Change Percent | -21.611256 |
| Fifty Two Week High | 21.73 |
| Fifty Two Week High Change | -15.744999 |
| Fifty Two Week High Change Percent | -0.72457427 |
| Fifty Two Week Low | 5.02 |
| Fifty Two Week Low Change | 0.96500015 |
| Fifty Two Week Low Change Percent | 0.1922311 |
| Fifty Two Week Range | 5.02 - 21.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,447,252,200,000 |
| Float Shares | 90,108,857 |
| Forward Eps | -1.08388 |
| Forward P E | -5.5218296 |
| Free Cashflow | -125,723,128 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 317 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.6407001 |
| Gross Profits | -117,799,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15882 |
| Held Percent Institutions | 0.8282 |
| Implied Shares Outstanding | 192,402,202 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore. |
| Long Name | Wave Life Sciences Ltd. |
| Market | us_market |
| Market Cap | 1,151,527,296 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_256557334 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -183,587,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,180,387,509 |
| Number Of Analyst Opinions | 16 |
| Open | 6.12 |
| Operating Cashflow | -184,007,008 |
| Operating Margins | -0.81833 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 65 6236 3388 |
| Previous Close | 6.13 |
| Price Eps Current Year | -7.1458426 |
| Price Hint | 2 |
| Price To Book | 2.166908 |
| Price To Sales Trailing12 Months | 16.038431 |
| Profit Margins | -2.5569901 |
| Quick Ratio | 10.929 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.14499998 |
| Regular Market Change Percent | -2.3654156 |
| Regular Market Day High | 6.12 |
| Regular Market Day Low | 5.94 |
| Regular Market Day Range | 5.94 - 6.12 |
| Regular Market Open | 6.12 |
| Regular Market Previous Close | 6.13 |
| Regular Market Price | 5.985 |
| Regular Market Time | 1,784,125,200 |
| Regular Market Volume | 210,631 |
| Return On Assets | -0.28226 |
| Return On Equity | -0.53104997 |
| Revenue Growth | 3.169 |
| Revenue Per Share | 0.403 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 192,402,202 |
| Shares Percent Shares Out | 0.1086 |
| Shares Short | 20,901,285 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 18,530,652 |
| Short Name | Wave Life Sciences Ltd. |
| Short Percent Of Float | 0.1348 |
| Short Ratio | 5.97 |
| Source Interval | 15 |
| Symbol | WVE |
| Target High Price | 43.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 21.9375 |
| Target Median Price | 18.5 |
| Total Cash | 544,590,976 |
| Total Cash Per Share | 2.831 |
| Total Debt | 15,715,000 |
| Total Revenue | 71,798,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.69835 |
| Two Hundred Day Average Change | -3.7133498 |
| Two Hundred Day Average Change Percent | -0.3828847 |
| Type Disp | Equity |
| Volume | 210,631 |
| Website | https://wavelifesciences.com |
| Zip | 18,936 |